Literature DB >> 27401214

Clinician Perspectives on Current Issues in Lung Cancer Drug Development.

Saiama N Waqar1, Philip D Bonomi2, Ramaswamy Govindan1, Fred R Hirsch3, Gregory J Riely4, Vassiliki Papadimitrakopoulou5, Dickran Kazandjian6, Sean Khozin6, Erin Larkins6, Dane J Dickson7, Shakun Malik8, Leora Horn9, Andrea Ferris10, Alice T Shaw11, Pasi A Jänne12, Tony S K Mok13, Roy Herbst14, Patricia Keegan6, Richard Pazdur6, Gideon M Blumenthal15.   

Abstract

Recent advances in molecularly targeted therapy and immunotherapy offer a glimmer of hope for potentially realizing the dream of personalized therapy for lung cancer. This article highlights current questions in clinical trial design, enrollment strategies and patient focused drug development, with particular emphasis on unique issues in trials of targeted therapy and immunotherapy. Published by Elsevier Inc.

Entities:  

Keywords:  Clinical trials; Immunotherapy; Lung cancer; Targeted therapy

Mesh：

Substances：

Year:  2016        PMID： 27401214      PMCID： PMC5131641          DOI： 10.1016/j.jtho.2016.05.009

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


  47 in total

Review 1.  Cell-free nucleic acids as biomarkers in cancer patients.

Authors:  Heidi Schwarzenbach; Dave S B Hoon; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2011-05-12       Impact factor: 60.716

Review 2.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

Review 3.  Evolving synergistic combinations of targeted immunotherapies to combat cancer.

Authors:  Ignacio Melero; David M Berman; M Angela Aznar; Alan J Korman; José Luis Pérez Gracia; John Haanen
Journal:  Nat Rev Cancer       Date:  2015-08       Impact factor: 60.716

4.  Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population.

Authors:  Drew W Rasco; Jingsheng Yan; Yang Xie; Jonathan E Dowell; David E Gerber
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

5.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

6.  Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.

Authors:  Andrew J Weickhardt; Benjamin Scheier; Joseph Malachy Burke; Gregory Gan; Xian Lu; Paul A Bunn; Dara L Aisner; Laurie E Gaspar; Brian D Kavanagh; Robert C Doebele; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

7.  A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.

Authors:  J C Ruckdeschel; D M Finkelstein; D S Ettinger; R H Creech; B A Mason; R A Joss; S Vogl
Journal:  J Clin Oncol       Date:  1986-01       Impact factor: 44.544

8.  Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.

Authors:  Helena A Yu; Camelia S Sima; James Huang; Stephen B Solomon; Andreas Rimner; Paul Paik; M Catherine Pietanza; Christopher G Azzoli; Naiyer A Rizvi; Lee M Krug; Vincent A Miller; Mark G Kris; Gregory J Riely
Journal:  J Thorac Oncol       Date:  2013-03       Impact factor: 15.609

9.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

10.  Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials.

Authors:  H A Tejeda; S B Green; E L Trimble; L Ford; J L High; R S Ungerleider; M A Friedman; O W Brawley
Journal:  J Natl Cancer Inst       Date:  1996-06-19       Impact factor: 13.506
View more
  1 in total

1.  Discovery of a Chiral DNA-Targeted Platinum-Acridine Agent with Potent Enantioselective Anticancer Activity.

Authors:  Shenjie Zhang; Xiyuan Yao; Noah H Watkins; P Keegan Rose; Sofia R Caruso; Cynthia S Day; Ulrich Bierbach
Journal:  Angew Chem Int Ed Engl       Date:  2020-09-29       Impact factor: 15.336
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.